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Alpha-synuclein (SYN) aggregation plays a pivotal role in the pathogenesis of Parkinson’s disease and other synucleinopathies. In this
multistep process, oligomerization of SYN monomers is the first step in the formation of fibrils and intracytoplasmic inclusions.
AlthoughSYN oligomers are generally considered to be the culprit of these diseases, the methodology currently available to follow-up
oligomerization in cells and in brain is inadequate.We developed a split firefly luciferase complementation system to visualize oligomer-
ization of viral vector-encoded SYN fusion proteins. SYN oligomerization resulted in successful luciferase complementation in cell
culture and inmousebrain.OligomerizationofSYNwasmonitorednoninvasivelywithbioluminescence imaging in themouse striatum
and substantia nigra up to 8 months after injection. Moreover, the visualized SYN oligomers retained their toxic and aggregation
properties in both model systems. Next, the effect of two small molecules, FK506 and (-)-epigallocatechin-3-gallate (EGCG), known to
inhibit SYN fibril formation, was investigated. FK506 inhibited the observed SYN oligomerization both in cell culture and in mouse
brain. In conclusion, the split firefly luciferase-SYN complementation assay will increase our insight in the role of SYN oligomers in
synucleinopathies and opens new opportunities to evaluate potential SYN-based neuroprotective therapies.
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Introduction
Over the last 15 years, it has become clear that the aggregation of
-synuclein (SYN) is causally linked to Parkinson’s disease
(PD) (reviewed by Deleersnijder et al., 2013). A fibrillar form of
SYN occurs in Lewy bodies (LBs) and Lewy neurites, patholog-
ical hallmarks of PD, which are also observed in multiple system
atrophy and dementia with LBs, and are together referred to as
synucleinopathies (Spillantini et al., 1997; Halliday et al., 2011).
SYN is generally thought to exist as a small intrinsically disor-
dered protein, without stable tertiary structure in solution that
adopts an-helical structurewhen bound tomembranes (David-
son et al., 1998). Recent literature has suggested that SYN may
adopt a stable tetrameric conformation under physiological con-
ditions, but these findings remain under debate (Bartels et al.,
2011; Wang et al., 2011; Binolfi et al., 2012; Fauvet et al., 2012;
Burre´ et al., 2013). During the aggregation process, disordered
monomeric or folded tetrameric SYN species assemble to form
soluble oligomers that, in turn, mature into insoluble fibrils. The
current prevalent hypothesis pinpoints the oligomers as the toxic
SYN species (Sharon et al., 2003; Karpinar et al., 2009; Paleol-
ogou et al., 2009;Winner et al., 2011; Colla et al., 2012; Kalia et al.,
2013). Conversion into insoluble fibrils might protect the cell
from these toxic SYN oligomers (Ross and Poirier, 2004).
Although inhibition of SYN oligomer formation is a logical
therapeutic strategy, the available tools to detectSYN oligomers
in cell culture are inadequate.Moreover,misfoldedSYN species
in the brain of rodent PD models can only be detected and thus
studied postmortem. In addition, the majority of postmortem
studies have focused on SYN fibrils rather than on SYN oli-
gomers. A bioluminescence-based protein fragment comple-
mentation assay (PCA) is a method to visualize protein–protein
interactions whereby luciferase is split and its N-terminal and
C-terminal parts are fused to either one of two interacting pro-
teins (Paulmurugan et al., 2002). A bioluminescent PCAbased on
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split Gaussia luciferase (Gluc) has already been developed to de-
tectSYNoligomers in cell culture (Putcha et al., 2010; Danzer et
al., 2011, 2012). However, the latter system cannot be translated
to living animals because the blue emission light is highly ab-
sorbed by surrounding tissue (Zhao et al., 2005) and the Gluc
substrate coelenterazine does not efficiently pass an intact blood–
brain barrier (BBB) (Pichler et al., 2004).
We and others previously demonstrated that the firefly lu-
ciferase (Fluc) is an ideal reporter for noninvasive biolumines-
cence imaging (BLI) in rodent brain (Deroose et al., 2006, 2009;
Massoud et al., 2008; Reumers et al., 2008; Heeman et al., 2011;
Vandeputte et al., 2014). Here, we engineered and characterized a
bioluminescent PCA based on a split-Fluc reporter system to
monitor SYN oligomerization, both in cell culture and in the
brain of living animals. Using this approach, we evaluated the
effect of the small molecules FK506 and (-)-epigallocatechin-3-
gallate (EGCG) on theSYN oligomerization process in cells and
in the mouse brain.
Materials andMethods
Viral vector construction and production. Overexpression of the different
genes of interest in cell culture was achieved via lentiviral (LV) vectors, in
which gene expression is controlled by the cytomegalovirus immediate
early (CMVie) promoter. First, FlucN-FKBP12-rapamycin binding
(FRB) and FKBP12-FlucC were cloned from pcDNA-FlucN-FRB and
pcDNA-FKBP12-FlucC (Paulmurugan and Gambhir, 2007) into the
pCHMWS transfer plasmid (Baekelandt et al., 2002). Next, FRB and
FKBP12 coding sequences were replaced by SYN or eGFP. Highly con-
centrated human immunodeficiency virus type 1 (HIV-1)-derived LV
vectors were produced as described previously, based on the triple trans-
fection method with a transfer plasmid, an envelope plasmid encoding
glycoprotein G of vesicular stomatitis virus and a second-generation
packaging plasmid (Ibrahimi et al., 2009). The resulting lentiviral vectors
are referred to as FlucN-FRB LV, FKBP12-FlucC LV, FlucN-SYN LV,
SYN-FlucC LV, and eGFP-FlucC LV, respectively. Viral titers were de-
termined using p24 ELISA (HIV-1 p24 ELISA kit, PerkinElmer, ng p24/
ml).
Overexpression of genes of interest in the mouse brain was achieved
with recombinant adeno-associated viral (AAV) vectors, in which gene
expression is controlled by the CMVie promoter. The different expres-
sion cassettes were cloned from pCHMWS transfer plasmids into the
pAAV transfer plasmid (Van der Perren et al., 2011). Highly concen-
trated AAV vectors of serotype 2/7 were produced as described previ-
ously, based on the triple transfection method with a transfer plasmid,
the AAV serotype 7 plasmid (pAAV7), and the AAV helper plasmid (Van
der Perren et al., 2011). Viral titers were determined as DNase resistant
genome copies (GCs) using a standard qPCR. Genome copies obtained
for the different productions ranged between 3  1011 and 7  1011
GC/ml. All experiments with LV andAAV vectors were performed under
biosafety level 2 conditions.
Cell culture and LV transduction. Human dopaminergic neuroblas-
toma SHSY5Y cells were maintained in DMEM (Invitrogen) supple-
mented with 15% heat-inactivated fetal calf serum (Harlan Sera-Lab,
International Medical), 1% nonessential amino acids (Invitrogen), and
50g/ml gentamycin (Invitrogen), referred to asDMEMcomplete. Cells
were maintained at 37°C and 5% CO2 in a humidified atmosphere and
were mycoplasma free. For the generation of stable overexpression cell
lines, 150,000 SHSY5Y cells were plated in a 24-well plate. The next day,
cells were transduced with either one or two LV vectors, normalized for
vector titers (p24/ml), for 24 h, after which the vector-containing me-
dium was replaced by DMEM complete. After 5 d in culture, cells were
controlled for overexpression of specific proteins via Western blot.
Luciferase activity assay. Stable overexpression cell lines were plated
out at a density of 40,000 cells/well in a 96-well plate. The next day,
medium was replaced with fresh medium, or medium supplemented
with 10 nM rapamycin (Sigma-Aldrich) and/or 1 M FK506 (Sigma-
Aldrich). The next day, the cells were washed with PBS and subsequently
lysed with 70 l of lysis buffer containing 50 mM Tris, pH 7.5, 200 mM
NaCl, 0.2%Nonidet P-40 (NP-40), 1 mM PMSF, and 10% glycerol. After
a freeze-thaw cycle, the lysate was centrifuged for 5 min at 1500  g. A
total of 5l of the supernatant was assayed for luciferase activity after the
addition of 25 l of ONE-Glo Luciferase Reagent (Promega). The pro-
duced light was measured at an integration time of 1 s with a GloMax
luminometer (Promega). Data were normalized to the total protein con-
centration, whichwas determined by the bicinchoninic acid assay (Pierce
Biotechnology) and are presented as relative light units permicrogramof
protein.
Western blot. Three days after transduction, cells were washed twice
with PBS and lysed with 100 l 1% SDS solution, supplemented with
protease cocktail inhibitor (RocheDiagnostics). Cell extracts were boiled
for 5 min and homogenized by 10 passages through a 30-gauge insulin
syringe followed by a final boiling step of 5 min; 25 g of total protein,
measured by the bicinchoninic acid assay, was separated on a 10% Bis-
Tris gel (Novex) and electroblotted for 1 h at 50 V onto PVDF mem-
branes (Bio-Rad). Membranes were blocked with 5% milk powder in
PBS supplemented with 0.1% Tween 20, and incubated with primary
antibodies goat anti-Fluc (1:3000, Promega) or mouse anti--tubulin
(1:1000, Sigma). Detection was performed after incubation with appro-
priate HRP-conjugated secondary antibodies (Dako) using chemilumi-
nescence (ECL-kit, Pierce).
Immunocytochemistry. Stable overexpression cell lines were generated
as described above, by cotransduction with FlucN-SYN LV and SYN-
FlucC LV. Cells transduced with wild-type (WT) SYN LV served as
positive controls; 70,000 cells were plated in gelatin-coated 8-well cham-
ber slides (Thermo Fisher Scientific). The next day, SYN aggregation
was induced by exposing the cells to oxidative stress (Ostrerova-Golts et
al., 2000; Gerard et al., 2010). The cells were exposed for 72 h to 100 M
H2O2 and 5 mM freshly prepared FeCl2 in DMEM complete, filtered
through a 0.20 m filter (Corning). Control cells were incubated with
fresh DMEM complete. After 3 d, the cells were washed with PBS and
fixed with 4% formaldehyde for 15 min. For the detection of oligomeric
or total SYN, the cells were washed for 10 min with PBS 0.1% Triton
(PBS-T). After a 1 h blocking step with donkey serum (Jackson Immu-
noResearch Laboratories), cells were incubated overnightwith oligomer-
specific antibody (rabbit polyclonal antibody A11, 1:400, Invitrogen) or
rabbit anti-SYN (AB5038, 1:200, Millipore). After 3 washing steps with
PBS for 5 min, the cells were incubated for 2 h with AlexaFluor-488-
conjugated donkey anti-rabbit antibody (1:500, Invitrogen) and washed
again 3 times with PBS. Finally, the cells were mounted using Mowiol
(Sigma-Aldrich) containing DAPI (1:10.000, Invitrogen). Cells were an-
alyzed with a confocal microscope (FV1000, Olympus) with a 488 nm
argon ion laser. Brightness, contrast, and background were adjusted
equally per corresponding staining using the Fluoview software. High
content analysis of SYN aggregation was performed as described previ-
ously; fibrillar SYN aggregates were detected via a Thioflavin-S
(Thio-S) staining (Gerard et al., 2010).
Biochemical analysis of SYN oligomers in cell culture. To detect and
discriminate different sizes of oligomers, a cross-linking protocol was
adapted with some minor modifications (Dettmer et al., 2013). Briefly,
2,000,000 cells either expressing WT SYN or FlucN-SYN  SYN-
FlucC were plated out. The next day, cells were collected by scraping,
washed with PBS, and resuspended in 200 l PBS with 1 Complete
Protease Inhibitor Mixture, EDTA-free (Roche Diagnostics). Immedi-
ately before use, a 50 mM stock of the cross-linker disuccinimidyl
glutarate (DSG) was prepared in DMSO. DSGwas applied on intact cells
because it was previously shown thatSYNoligomers are sensitive to cell
lysis (Dettmer et al., 2013). The samples were incubated with 1 mM DSG
or DMSO for 30 min at 37°C in a shaking incubator. The cross-linking
reaction was quenched by addition of 1 M Tris, pH 7.5, to 50 mM final
concentration and incubated for 15 min at room temperature. Next,
samples were lysed by 15 s sonication. Finally, the samples were ultracen-
trifuged (Optima TLX, Beckman) for 30 min at 200,000  g to recover
the cytosolic fraction from the supernatant. A total of 10 g of protein
was loaded on 4%–12% Bis-Tris gels (for WT SYN) or 3%–8% Tris-
acetate gels (for Fluc-tagged SYN) (Novex). After electroblotting, the
PVDF membranes were incubated for 30 min in 0.4% PFA and rinsed
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twicewith PBS (Lee andKamitani, 2011;Dettmer et al., 2013;Newman et
al., 2013). Blocking and immunodetection were performed as described
above. The effectiveness of cross-linking was analyzed by immunoblot-
ting with the monoclonal antibody 15G7, which specifically detects hu-
man SYN (rat anti-human SYN 15G7, 1:100, Enzo Life Sciences).
Other antibodies that were used are rabbit anti-DJ1 (1:1000, Covance),
goat anti-Fluc (1/3000, Promega), mouse anti--actin (1:1000, Sigma),
and goat anti--actin (1:1000, Santa Cruz Biotechnology).
Stereotactic injections. All animal experiments were performed in ac-
cordance with the European Communities Council Directive of Novem-
ber 24, 1986 (86/609/EEC) and approved by the Bioethical Committee of
the KU Leuven (Belgium). Adult male and female 12- to 15-week-old
albino C57BL/6-Tyr c-2J/J mice (stock #000058, The Jackson Laboratory)
were housed under a 12 h light/12 h dark cycle with free access to food
and water. Anesthesia was induced by intraperitoneal injection of a mix-
ture of ketamine (75 mg/kg Ketalar, Pfizer) andmedetomidine (1 mg/kg
Domitor, Pfizer). The mice were placed in a stereotactic head frame
(Stoelting). A midline incision of the skin was made and a small hole
drilled in the skull at the appropriate location, using bregma as reference.
Coordinates to target mouse striatumwere anteroposterior 0.5 mm,me-
diolateral2.0mm relative to bregma, and dorsoventral3.0 to 2.0mm
from the dural surface. Coordinates for mouse substantia nigra (SN)
were anteroposterior 3.1 mm, mediolateral 1.2 mm, and dorsoven-
tral 4.0 mm. The different AAV vectors were normalized by titer and
volume, resulting in injection of an equal amount of GC per vector and 2
l (in the striatum and SN) or 4 l (in the striatum) of a mixture of 2
vectors was injected. The vectors were injected at a rate of 0.25 l/min
with a 30-gauge needle (VWR International) on a 10 l syringe (Hamil-
ton). After the injection, the needle was left in place for an additional 5
min to allow diffusion before being slowly withdrawn from the brain.
Anesthesia was reversed with an intraperitoneal injection of atipamezol
(0.5 mg/kg Antisedan, Pfizer). The number of animals is indicated in the
figure legends.
In vivo bioluminescence imaging. Themice were imaged in an IVIS 100
system (PerkinElmer). Anesthesia was performed in an induction cham-
ber with 2% isoflurane (Halocarbon Products) in 100% oxygen at a flow
rate of 1 L/min and maintained in the IVIS with a 1.5% mixture at 0.5
L/min. Because fur negatively influences BLI signals (Deroose et al.,
2006), the heads of themicewere shaved before each imaging session; 126
mg/kg D-luciferin (Promega) dissolved in PBS (15 mg/ml) was injected
intravenously. Immediately after injection, the mice were placed in the
prone position in the IVIS and consecutive 1 min frames were acquired
until the maximum signal, between 1 and 5 min after luciferin injection,
was reached. The data are reported as the photon flux (p/s) from a 1.5
cm2 circular region of interest around the head.
Perfusion and immunohistochemistry. Mice were deeply anesthetized
by intraperitoneal injection of pentobarbital (60mg/kg, Nembutal, Ceva
Sante´ Animale) and perfused transcardially with saline followed by ice-
cold 4%PFA inPBS. After fixation overnight, 50-m-thick coronal brain
sections weremade with a vibratome (HM650V,Microm). Immunohis-
tochemistry was performed on every fifth section throughout the whole
striatum or SN. Free-floating sections were pretreated with 3%hydrogen
peroxide (Chem-Lab) in PBS-T for 10min and incubated overnight with
rabbit anti-tyrosine hydroxylase (TH, 1:1000, Millipore) or rat anti-
dopamine active transporter (1:1000,Millipore) in PBS-Twith 10%nor-
mal goat or swine serum (Dako). Appropriate biotinylated secondary
antibodies were used (1:300, Dako), followed by incubation with
streptavidin-HRP complex (1:1000, Dako). For the detection of (phos-
phorylated) SYN, stainings were performed in fresh TBS and sections
were washed with TBS with 0.1% Triton X-100 (TBS-T). Sections were
pretreated for 10 min with 10%methanol and 3% hydrogen peroxide in
TBS, followed by 1 h incubation in 10% swine serum. Next, they were
incubated overnight with rabbit anti-SYN (AB5038, 1:5000, Millipore)
ormouse antibodies againstSYNphosphorylated at position serine 129
(S129p SYN) (11A5, 1:5000, Elan Pharmaceuticals) (Anderson et al.,
2006). Appropriate biotinylated secondary antibodies were used (1:600,
Dako), followed by incubationwith streptavidin-HRP complex in TBS-T
(1:1000,Dako). Immunoreactivity was visualized usingDAB (0.4mg/ml,
Sigma-Aldrich) or Vector SG (Vector Laboratories) as a chromogen.
After a dehydration series, stained sections were mounted with DPX
(Sigma-Aldrich) and visualized with a light microscope (Leica
Microsystems).
For fluorescent double stainings, sections were washed in PBS and
incubated overnight with mouse anti-SYN (LB509, 1:100, Invitrogen)
or rat anti-SYN (15G7, 1:200, Enzo Life Sciences) and chicken anti-
ubiquitin (1:200, Sigma) or goat anti-DARPP32 (dopamine- and cAMP-
regulated phosphoprotein of 32 kDa, 1:50, Santa Cruz Biotechnology) or
chicken anti-TH (1:500, Aves Laboratories) and rabbit anti-neuronal
nuclear antigen (NeuN) (1:1000, Millipore) in PBS-T with 10% donkey
serum. After 3 washing steps with PBS-T, sections were incubated for 2 h
with appropriate Alexa488-, Alexa555-, and Alexa633-labeled secondary
antibodies. Next, the sections were washed in PBS-T and mounted with
Mowiol. Fluorescencewas detectedwith a confocalmicroscope (FV1000,
Olympus) with a 488, a 559, and a 633 nm laser.
For the detection of fibrillar SYN species, free-floating sections were
washed 2 times for 1 min in AD. Next, they were incubated for 5 min in
freshly prepared 1% Thio-S (Sigma-Aldrich) in distilled water, followed
by 5 min of incubation in 70% ethanol. After 3 brief washing steps with
AD, sections were mounted with Mowiol. Fibrils were detected with a
488 nm laser.
Biochemical analysis ofSYN oligomers inmouse brain. For the analysis
of SYN oligomers in mouse brain, the right striatum of two mice per
group was isolated and homogenized in 200 l PBS with 1 Complete
Protease Inhibitor Mixture, EDTA-free. The brain homogenates were
then divided in 100 l for cross-linker treatment and 100 l for DMSO
treatment. Cross-linking and immunodetection were performed as de-
scribed for cell culture experiments.
Stereological quantification. To quantify the degree of dopaminergic
degeneration in the SN, the total number of TH-positive cells in the
injected and contralateral SN was measured with an unbiased stereo-
logical counting method using the optical fractionator principle in a
computerized system, as described previously (StereoInvestigator,
MicroBright-Field) (Oliveras-Salva´ et al., 2013). Every fifth section was
analyzed, with a total of 5 sections for each animal. The volume of TH-
immunoreactive fibers in the striatum was determined by stereological
volume measurements based on the Cavalieri method as described pre-
viously (Baekelandt et al., 2002; Vercammen et al., 2006). Every fifth
sectionwas analyzed, with a total of 6 sections for each animal. The values
for cell loss in the SN and fiber loss in the striatum are expressed relative
to the control hemisphere.
Evaluation of inhibition of SYN oligomerization by FK506 and EGCG.
To evaluate the effect of FK506 and EGCG on SYN oligomerization in
cell culture, a stable overexpression cell line was generated as described
above, by cotransduction with FlucN-SYN LV and SYN-FlucC LV for
24 h, after which the vector-containing mediumwas replaced by DMEM
complete. To verify whether FK506 and EGCG influence luciferase activ-
ity, a cell line overexpressing full-length Fluc was generated in the same
way by transduction with eGFP-T2A-Fluc LV. After 5 d in culture,
overexpression of specific proteins was verified via Western blot. A total
of 30,000 cells were plated in a 96-well plate. The next day, medium was
replaced with fresh DMEM complete complemented with either 10 M
FK506 (Sigma-Aldrich), 25 M EGCG (Sigma-Aldrich), or DMSO
(Sigma-Aldrich), resulting in 0.1% DMSO in all conditions. Luciferase
activity was determined 24 h after addition of the compounds. The lu-
ciferase activity from cells expressing FlucN-SYN  SYN-FlucC was
normalized to that of cells expressing eGFP-T2A-Fluc.
To assess the effect of FK506 and EGCG on SYN oligomerization in
mouse brain, 10-week-old female albino FVB/N mice (Janvier) were
stereotactically injected as described above. The experimental group was
injectedwith 2l of a 1:1mixture of FlucN-SYNandSYN-FlucCAAV
vectors in the striatum. A control group was injected with 2 l of eGFP-
T2A-Fluc AAV. Daily intraperitoneal injections with freshly prepared
compounds were initiated 1 d after stereotactic surgery and continued
for 28 d. FK506 (Cayman Chemicals) was dissolved in 10% ethanol in
0.9% sterile saline containing 1%Tween 80, and a final dose of 5mg/kg/d
was administered (Hong et al., 2010). EGCG (Cayman Chemicals) was
dissolved in 0.9% sterile saline, and a final dose of 20 mg/kg/d was ad-
ministered (Rezai-Zadeh et al., 2005; Wang et al., 2012). A similar
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amount of 10% ethanol in 0.9% sterile saline containing 1% Tween 80
was used as placebo. The BLI signal from mice expressing FlucN-SYN
 SYN-FlucC was normalized to that of mice expressing eGFP-T2A-
Fluc, per treatment and per time point.
Statistical analysis. All statistical analyses were performed in Prism 5.0
(GraphPad Software). For multiple group comparisons at a single time
point (e.g., luciferase assays in cell culture), one-way ANOVA followed
by a post hoc Bonferroni or Dunnett’s test to correct for multiple testing
was used. In case of non-normality, the nonparametric equivalent
(Kruskal–Wallis test) was chosen, followed by Dunn’s test. In case only
two groups were compared, a Student’s t test or Mann–Whitney U test
(non-normality) was used. For multiple comparisons at different time
points (e.g., BLI of different groups of animals over time), repeatedmea-
sures mixed-model ANOVA was performed, followed by a Bonferroni
post test.
Results
Visualization ofSYN oligomerization in cell culture using
split-Fluc LV vectors
In a bioluminescent PCA, the N-terminal (FlucN) and
C-terminal (FlucC) part of Fluc are fused to each of two interact-
ing proteins (Fig. 1A). Physical interaction of the latter two pro-
teins has the potential to reconstitute the Fluc reporter protein,
recovering activity and resulting in the production of visible light
upon addition of the substrate luciferin. The orientation of the
Fluc components in relation to the protein of interest greatly
influences the functionality of the complemented Fluc protein
(Paulmurugan and Gambhir, 2007; Luker et al., 2011; Leng et al.,
2013). Moreover, for the development of a fluorescent PCA, dif-
ferent orientations of the two halves of GFP, GFP-N and GFP-C,
in relation to SYN were compared, showing the highest com-
plementation efficiency when GFP-N was positioned at the
N-terminal andGFP-C at theC-terminal ofSYN (Outeiro et al.,
2008). For this reason, FlucN was positioned at the N-terminal
and FlucC at the C-terminal part of the proteins of interest (Fig.
1B). To monitor SYN oligomerization, both FlucN and FlucC
were fused to SYN. As positive controls, FlucN and FlucC fused
to the FRB domain or FKBP12, respectively, were constructed.
The fusion construct eGFP-FlucC was generated as a negative
control. After transduction of SHSY5Y cells with single split-Fluc
Figure1. Split-firefly luciferase reporter assay to visualizeSYNoligomerization in cell culture.A, Principle of a bioluminescent PCA. FlucN and FlucC are fused to two interacting proteins. In case
of interaction between the two proteins, the Fluc protein will be complemented, restoring its enzymatic activity. In the presence of its substrate luciferin, protein–protein interaction will lead to
production of light.B, Design of split-Fluc fusion constructs, drawn to scale. C, Western blot showing expression of different protein fusions, detectedwith a polyclonal anti-Fluc antibody in SHSY5Y
cells transduced with split-Fluc LV vectors. This antibody allows detection of both FlucN and FlucC. D, Luciferase activity of SHSY5Y cells transduced with different combinations of split-Fluc LV
vectors. Transductionwithone split-Fluc LVvector didnot result in luminescence. The functionality of the split-luciferase systemwasvalidatedby theknown rapamycin-induced interactionbetween
FRB and FKBP12 (purple bars), which was inhibited by addition of FK506. Data are mean SEM. Statistical analysis: one-way ANOVA combined with Bonferroni correction for multiple testing
(F(2,54) 28.5). ***p 0.0001. ** p 0.01. Red bars represent cells transducedwith at least one split-Fluc-aSYN LV. Cells transducedwith two split-Fluc-SYN LVs showed 11–160 times higher
BLI signals compared with cells transduced with different combinations of split-Fluc LV vectors, showing that interaction between two or more SYN proteins results in productive luciferase
complementation. Data aremean SEM. Statistical analysis: one-way ANOVA combinedwith Bonferroni correction formultiple testing (F(4,90) 80.0). ***p 0.0001. Data are pooled data from
3 independent experiments; n 19 per condition.
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LV vectors, expression of the respective protein fragments was
evidenced (Fig. 1C). As expected, single split-Fluc LV vectors did
not result in luciferase activity (Fig. 1D).
As a first step to validate the functionality of the split-
luciferase system, we analyzed the known rapamycin induced
interaction between FRB and FKBP12 (Fig. 1D, purple bars).
SHSY5Y cells cotransduced with FlucN-FRB and FKBP12-FlucC
LV vectors showed a 2000-fold increase in BLI signal upon
addition of 10 nM rapamycin (p 0.0001). This interaction was
inhibited twofold upon addition of 1 M FK506 (p  0.01).
Neither rapamycin nor FK506 inhibited luciferase activity as such
(data not shown).
To monitor SYN oligomerization, cells were transduced
with FlucN-SYN  SYN-FlucC LV vectors and compared
with control cells transduced with different combinations of
split-Fluc LV vectors (Fig. 1D, red bars). The BLI signal of cells
transduced with both split-Fluc-SYN LV vectors was11-fold
higher comparedwith cells transducedwith one split-Fluc-SYN
LV vector in combination with a split-Fluc control LV vector
(p  0.001). The BLI signal of cells expressing both split-Fluc-
SYN fusion proteins was even 160 times higher compared with
cells expressing FlucN-FRB  eGFP-FlucC (p  0.001). These
data indicate that interaction between two or more SYN pro-
teins results in productive luciferase complementation.
Luciferase complementation in cell culture results from
SYN oligomerization
To define the specificSYN species at the origin of the BLI signal,
cells expressing FlucN-SYN and SYN-FlucC were subjected to
immunocytochemical analysis. Under standard culture condi-
tions, we identified oligomeric SYN species with the oligomer-
specific A11 antibody (Kayed et al., 2003), comparable with cells
expressing untaggedWT SYN (Fig. 2A). In agreement with our
previous observations (Gerard et al., 2010), SYN accumulation
was not detected under standard culture conditions (Fig. 2B),
suggesting that the bimolecular interaction detected in the lu-
ciferase complementation assay represents preaggregate oligo-
meric SYN species.
Next, we evaluated whether the rather large Fluc-tags
(FlucN 44 kDa; FlucC 17 kDa, respectively), might affect the
aggregation properties ofSYN. Cells expressing FlucN-SYN
SYN-FlucC were subjected to oxidative stress to induce SYN
aggregation (Gerard et al., 2010). Cells expressing untagged WT
SYN were analyzed in parallel. Immunocytochemical stainings
Figure2. Immunocytochemical characterizationof split Fluc-taggedSYN species in cell culture.A, Under standard conditions,SYNoligomers (arrowheads, detectedwith anoligomer-specific
A11 antibody) are present in SHSY5Y cells expressing FlucN-SYNSYN-FlucC (left). Oligomerswere also present in cells expressing untaggedWTSYN (middle, arrowheads). Oligomers could
not be detected in empty cells (right).B, Immunocytochemical stainingwith an anti-SYN antibody. Under oxidative stress conditions, accumulation ofSYN (arrows) is induced in cells expressing
FlucN-SYN SYN-FlucC (left), comparable with cells expressing untagged WT SYN (middle). These accumulations were absent in standard conditions. A, B, Scale bar, 20m. C, D, High
content automated quantification ofSYN fibril formation. C, Data are mean SEM (n 6 per condition). Statistical analysis: one-way ANOVA combined with Bonferroni correction for multiple
testing (F(5,30) 198.5). ***p 0.001. D, Pictures taken with IN Cell Analyzer for high-content analysis, showing detection ofSYN fibrils (arrowheads) via Thio-S staining. Scale bar, 100m.
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revealed increased intensity of SYN immunoreactivity mainly
near the cell borders with some clear accumulations, similar to
cells expressingWTSYN (Fig. 2B). High content analysis-based
automated quantification, based on the detection of fibrillary
SYN via Thio-S staining, showed a 3.2-fold increase in fibril
formation in cells expressing FlucN-SYN SYN-FlucC (p
0.001), which was comparable with the increase in cells express-
ing untaggedWT SYN (Fig. 2C,D), underscoring that the Fluc-
tags do not significantly affect the aggregation behavior of SYN
under oxidative stress conditions. Of note, SYN oligomeriza-
tion could not bemonitored with the bioluminescent PCA under
oxidative stress conditions because Fluc activity is sensitive to
reactive oxygen species (Czupryna and Tsourkas, 2011; and data
not shown).
In conclusion, the bioluminescent PCA can detect SYN oli-
gomerization by productive luciferase complementation in cell
culture.
Biochemical analysis ofSYN oligomers in cell culture
Next, we evaluated the biochemical nature of the SYN oligo-
mers that were generated in SHSY5Y cells expressing FlucN-
SYN  SYN-FlucC. to trap native assemblies of SYN is
through cross-linking on intact cells using small, cell-permeable
cross-linkers. This approach previously allowed detection of dif-
ferent sizes of endogenous SYN oligomers in human erythro-
leukemia cells (Bartels et al., 2011; Dettmer et al., 2013). First, we
verified whether this cross-linking technique allowed detection
of oligomers of overexpressed WT untagged SYN in SHSY5Y
cells. We used DSG, a cell-permeable cross-linker that forms co-
valent nonreducible bonds between lysine residues, of which
SYN contains 15. Immunoblotting after cross-linking revealed
different sizes ofSYNoligomers in SHSY5Y cells overexpressing
WT SYN, with dimers and oligomers of 	85 kDa and 	100
kDa as the most prominent oligomers (Fig. 3A). As a positive
control for the cross-linking technique, we also detected endog-
enous DJ1 in its known physiological dimeric form (Fig. 3A).
Next, we applied the cross-linking protocol on SHSY5Y cells
that either expressed FlucN-SYN or SYN-FlucC or cells ex-
pressing both fusion proteins (Fig. 3B). In the cells expressing
both fusion proteins, a distinct band of 	90 kDa was detected,
together with other high-molecular-weight (HMW) oligomers.
The size of this 	90 kDa band, and the fact that it was not de-
tected in the other two cell lines strongly suggests that this band
represents a dimer formed by FlucN-SYN and SYN-FlucC. Of
note, in cells expressing FlucN-SYN, cross-linking also revealed
the presence of a dimer (of 	116 kDa) and other HMW oligo-
mers, although to a weaker extent. In cells expressing SYN-
FlucC, the different oligomers were more difficult to distinguish.
In conclusion, oligomers of different sizes, ranging from dimers
to HMW oligomers, are generated in cells expressing FlucN-
Figure 3. Cross-linking revealsSYN oligomers of different sizes in cell culture. A, B, Cytosolic fractions from SHSY5Y cells, treated with DMSO () or 1mM DSG (), were loaded and analyzed
by immunoblotting. A, Cytosolic fractions from empty cells or cells overexpressing WT untaggedSYN were analyzed. Immunodetection with the 15G7 antibody revealedSYN monomers and
oligomers of different sizes, with dimers and	85 kDa and	100 kDa oligomers as the most prominent oligomers. The 15G7 antibody does not detect endogenous SYN. The efficiency of
cross-linkingwas evidenced by the detection of DJ1 dimers. Detection of-actinwas impaired by the cross-linking, as previously described (Newman et al., 2013).B, Immunodetection of cytosolic
fractions from cells expressing FlucN-SYN,SYN-FlucC, or both fusion proteins with the 15G7 and Fluc antibodies revealed the presence of monomers and oligomers of different sizes. The size of
the	90 kDa band detected in cells expressing both fusion proteins and the fact that this bandwas not detected in the other two cell lines strongly suggest that this band represents a dimer formed
by FlucN-SYN andSYN-FlucC.
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SYN  SYN-FlucC, which correspond to the successful lu-
ciferase complementation signal.
Noninvasive imaging of SYN oligomerization in mouse
striatum up to 8 months after injection using split-Fluc AAV
vectors
Next, we set out tomonitorSYNoligomerization noninvasively
in the mouse brain using our bioluminescent PCA. After validat-
ing the system in cell culture, we produced split-Fluc AAV vec-
tors.We opted for AAV2/7 vectors instead of LV vectors for the in
vivo experiments because of their higher transduction efficiency
of dopaminergic neurons in the brain (Van der Perren et al.,
2011). Equal titers of two AAV vectors (a total of 1.8  108 GC
per animal) were stereotactically injected in the striatum of al-
binomice (n 4 per group).One groupwas injectedwith FlucN-
SYN  SYN-FlucC AAV vectors and a control group with
FlucN-FRB SYN-FlucC AAV vectors to control for aspecific
luciferase signal. The animals were regularly scanned over time,
until 8 months after injection. The group injected with the two
split-Fluc-SYNAAV vectors showed 5.9-fold higher BLI signals
at all time points compared with the control group (Fig. 4A,B;
p  0.0002). These data were confirmed in an independent ex-
periment with new vector productions (data not shown). This
demonstrates that, in line with the cell culture experiments,
SYN oligomerization results in productive luciferase comple-
mentation in vivo.
Long-term noninvasive monitoring of SYN oligomerization
in the same groups of animals allowed us to identify particular
BLI kinetics. Remarkably, in the mice injected with the two split-
Fluc-SYN AAV vectors, the BLI signal steadily increased until 5
weeks after injection In twomice, the BLI signal peaked at 3weeks
after injection and in two mice at 5 weeks after injection, which
was followed by a gradual decrease in BLI signal until 9 weeks
after injection, after which the signal remained stable until 8
months after injection (Fig. 4B). These kineticswere not observed
in the control group, indicating that the specific BLI kinetics in
the mice injected with the two split-Fluc-SYN AAV vectors can
be attributed to the SYN oligomerization process.
The mice were perfused at 8 months after injection for de-
tailed histological analysis (Fig. 4C–H). SYN overexpression
was detected in the striatum of both groups (Fig. 4C). Double
immunofluorescent stainings revealed that SYN was predomi-
nantly expressed in the dopaminoceptive medium spiny neurons
of the striatum (Fig. 4D). To assure that the tagged SYN species
are still susceptible to pathological modifications, we performed
additional stainings for typical phenotypic markers. In both
groups, transduced cells contained aggregated, phosphorylated
S129p and ubiquitinated SYN (Fig. 4E–G), features that are
associated with SYN pathology. In addition, fibrillar SYN spe-
cies were detected by Thio-S staining (Fig. 4H). Compared with
the noninjected side, there were no apparent signs of cell death in
the injected striatum (Fig. 4D).
Together, these data indicate that, following injection of split-
Fluc AAV vectors in the striatum, SYN oligomerization can be
monitored noninvasively by BLI. Moreover, the tagged SYN
species still generate pathologically relevant SYN species.
Biochemical analysis of SYN oligomers in mouse striatum
Next, we aimed to analyze the presence and size of the SYN
oligomers generated in vivo. To our knowledge, cross-linking of
endogenous or overexpressedSYN inmouse brain has not been
demonstrated before. Therefore, we first performed cross-linking
on transgenic Thy1-A30PSYN mice (Kahle et al., 2000), WT
mice injected with an AAV encoding WT untagged SYN, and
WT mice as negative control. In transgenic Thy1-A30PSYN
mice and in mice injected with an AAV-SYN, cross-linking re-
vealed different sizes ofSYNoligomers, withmainly dimers and
	65 kDa and	85 kDa oligomers (Fig. 5A). Interestingly, inmice
injected with AAV-SYN, SYN dimers could even be detected
without cross-linking (Fig. 5A). In line with the cell culture ex-
periments, the effectiveness of cross-linkingwas demonstrated by
the detection of DJ1 dimers (Fig. 5A). Next, we applied the cross-
linking protocol to detectSYN oligomers in brain homogenates
ofmice 4 d, 4weeks, or 17weeks after injectionwith FlucN-SYN
 SYN-FlucC AAV vectors. The expression of the fusion pro-
teins markedly increased between 4 d and 4 weeks after injection
(Fig. 5B). From 4 weeks onwards, monomers and oligomers could
be detected in cross-linked brain extracts with antibodies against
SYNandFluc (Fig. 5B). In linewith the cell culture experiments, an
oligomeric band of	90 kDa, suggesting that a dimer between the
two fusion proteins could be distinguished. These findings suggest
that, in mouse brain, SYN oligomers ranging from dimers to
HMWoligomers are formed, which are presumably responsible for
the successful luciferase complementation.
BLI ofSYN oligomerization and dopaminergic cell death in
mouse SN
In a next step,wemonitoredSYNoligomerization in the SN, the
main region affected in PD patients. As in the striatum, amixture
of two split-FlucAAVvectors (a total of 7.0 108GCper animal)
was stereotactically injected in the SN of albino mice. One group
was injected with FlucN-SYN SYN-FlucC AAV vectors and
a control group was injectedwith FlucN-FRBSYN-FlucCAAV
vectors (n 5 per group). The animals were scanned regularly until
6 months after injection (Fig. 6A,B). In line with striatal injections,
the BLI signal of the group injected with FlucN-SYN  SYN-
FlucC AAV vectors was 5.8-fold higher over all time points than
the control group (Fig. 6A,B; p 0.002). In both groups, the BLI
signal increased until 1 or 3 weeks after injection, followed by a
decrease until 6 weeks after injection after which the signal re-
mained stable up to 6 months after injection These data were
confirmed in an independent experiment in which the animals
were scanned until 2 months after injection (data not shown).
Again in both groups, histological analysis revealed SYN
pathology by the presence of aggregated SYN and SYN
phosphorylated at S129 (Fig. 6C,D). Immunohistological de-
tection of TH revealed a distinct dopaminergic cell death in
the SN of both groups (Fig. 6E). Immunostaining for the do-
pamine active transporter and the pan-neuronal marker
NeuN confirmed loss of dopaminergic neurons in the SN
(data not shown and Fig. 6G). Compared with the noninjected
side, stereological quantification revealed 88  6% dopami-
nergic cell loss in mice expressing FlucN-SYN  SYN-
FlucC and 73 9% dopaminergic cell loss in mice expressing
FlucN-FRB  SYN-FlucC, respectively (Fig. 6F ). In mice
perfused at 2 months after injection, a similar degree of dopa-
minergic degeneration was detected (data not shown). Triple
immunofluorescent stainings at 6 months after injection re-
vealed that SYN is mainly confined to the surviving dopami-
nergic neurons and the surrounding nondopaminergic
neurons (Fig. 6G). The dopaminergic cell loss was further
corroborated by loss of dopaminergic fibers in the striatum
(Fig. 6H ). Stereological quantification of the striatal TH-
positive volume revealed a 75  14% reduction in mice ex-
pressing FlucN-SYN  SYN-FlucC and 73  22%
reduction in mice expressing FlucN-FRB  SYN-FlucC, re-
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spective to the contralateral side (Fig. 6F ). The degree of do-
paminergic neurodegeneration is comparable with our
previous observations with AAV-mediated overexpression of
untagged WT SYN in the mouse SN (Oliveras-Salva´ et al.,
2013). Together, these data show that the tagged aSYN species
retain their pathological properties in vivo.
FK506 inhibitsSYN oligomer formation
In a next step, we evaluated the effect of two small-molecule
inhibitors on SYN oligomerization, first in cell culture and sub-
sequently in mouse brain using the bioluminescent PCA. Previ-
ously, we revealed a direct link between FKBPs and SYN
aggregation (Gerard et al., 2006, 2010; Meuvis et al., 2010; Del-
Figure 4. Noninvasive BLI ofSYN oligomerization in mouse striatum. A, B, Different combinations of different split-Fluc AAV vectors as indicated were injected in the right striatum
of albinomice (n 4 per group). Animals were scanned until 8 months after injection A, Representative BLI images at 3 weeks after injection are shown, revealing a BLI signal originating
from the site of injection. B, Mice expressing FlucN-SYN SYN-FlucC showed a sixfold higher BLI signal and different kinetics compared with the control group. Data are mean
SEM. Statistical analysis: two-way repeated-measures ANOVA (F(1,50) 90.4). ***p 0.0002. C, Immunohistochemical stainings showing SYN expression in the striatum of both
groups. Scale bar, 100m. D, Double immunofluorescent stainings show thatSYN (red) is mainly expressed in medium spiny neurons, detected by a DARPP32 antibody (green). Scale
bar, 100m. E, F, Immunohistochemical stainings showed that, in both groups, transduced cells contained aggregatedSYN (arrows, detected with an antibody againstSYN) (E) and
phosphorylated S129pSYN (detected with an antibody against S129pSYN) (F ). E, F, Scale bar, 25m. G, Double immunofluorescent stainings show colocalization ofSYN (green)
and ubiquitin (red) in the striatum. H, Thio-S staining shows the presence of fibrillar SYN in the injected striatum. G, H, Scale bar, 50m.
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eersnijder et al., 2011). FKBP12 was shown to increase SYN
fibril formation and FK506, by inhibiting FKBP12, to reduce the
number of SYN fibrils and to protect against cell death in a cell
culture model for synucleinopathy (Gerard et al., 2010). In addi-
tion, chronic FK506 administration reduced SYN aggregation
and neurodegeneration in mice overexpressing SYN in the
striatum (Gerard et al., 2010).Whether FK506 also inhibitsSYN
oligomerization has remained unexplored.
EGCG, the main polyphenolic constituent of green tea, has
generated substantial interest as potential modulator of a variety
of neurodegenerative diseases (Mandel et al., 2011). In vitro,
EGCG inhibits SYN fibrillogenesis by direct binding to natively
Figure 5. Cross-linking revealsSYN oligomers of different sizes in mouse brain. Cytosolic fractions frommouse brain homogenates that were treated with DMSO () or 1 mM DSG () were
analyzed. The two lanes per condition represent two different animals. A, Analysis of cytosolic fractions fromWTmice, Thy1–A30PaSYNmice, or mice injected with AAV-WT-SYN. Immunodetec-
tion with the 15G7 antibody of WT untagged SYN in mouse brain revealed SYN monomers and oligomers of different sizes, with mainly dimers and	65 kDa and	85 kDa oligomers. The
efficiency of cross-linking was evidenced by the detection of DJ1 dimers. Detection of-actin was impaired by the cross-linking, as previously described (Newman et al., 2013). The 15G7 antibody
does not detect endogenous mouse SYN. B, Analysis of cytosolic brain homogenates from mice at 4 d, 4 weeks, or 17 weeks after injection of FlucN-SYN  SYN-FlucC AAV vectors.
Immunodetection with the 15G7 and Fluc antibodies revealedSYN monomers and oligomers in the cross-linked samples, ranging from dimers to HMW oligomers, from 4 weeks after injection
onwards.
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Figure 6. Noninvasive BLI ofSYN oligomerization and dopaminergic neurodegeneration inmouse SN.A,B, Different combinations of split-Fluc AAV vectors as indicatedwere injected in the right SN of
albinomice (n5pergroup).Animalswerescanneduntil 6monthsafter injectionA, RepresentativeBLI imagesat3weeksafter injectionare shown, revealingaBLI signaloriginating fromthesiteof injection.
B,Mice expressingFlucN-SYNSYN-FlucC showeda sixfoldhigherBLI signal comparedwith the control group.DataaremeanSEM.Statistical analysis: two-way repeated-measuresANOVA (F(1,56)
19.80).**p0.002.C,D, Immunohistochemicalstainingsshowedthat, inbothgroups,cells intheSNcontainedaggregatedSYN(arrows,detectedwithanantibodyagainstSYN)andphosphorylatedS129p
SYN (detectedwith an antibody against S129pSYN). C,D, Scale bar, 25m.E, Immunohistochemical detection of TH reveals a distinct dopaminergic degeneration in the injected SN in both groups. Scale
bar,250m.F,Stereologicalquantificationrevealed886%dopaminergiccelllossinmiceexpressingFlucN-SYNSYN-FlucC(n5)and739%dopaminergiccelllossinmiceexpressingFlucN-FRBSYN-FlucC
(n5),respectivetothecontralateralside.Therewasnostatisticaldifferenceinthedegreeofcelllossbetweenbothgroups(Student’sttest,T(8)1.4;p0.19).StereologicalquantificationofthestriatalTH-positivevolume
revealeda7514%reduction inmiceexpressingFlucN-SYNSYN-FlucC (n4)and7322%reduction inmiceexpressingFlucN-FRBSYN-FlucC (n3), respective to thecontralateral side.Therewasno
statisticaldifferenceinthedegreeofdopaminergicfiberlossbetweenbothgroups(Student’sttest,T(5)0.07;p0.94).G,TripleimmunofluorescentstainingforSYN,TH,andNeuN,showingthatSYNismainlyexpressed
inthesurvivingdopaminergicneuronsandsurroundingnondopaminergicneurons.Scalebar,100m.H, ImmunohistochemicaldetectionofTHinthestriatum.Scalebar,1mm.
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unfolded SYN, thereby preventing its conversion into toxic,
on-pathway aggregation intermediates, through promotion of
nontoxic, off-pathway, seeding-incompetent SYN oligomers
(Ehrnhoefer et al., 2008; Caruana et al., 2011). Moreover, EGCG
also remodels preexisting SYN oligomers and fibrils into
smaller, benign aggregates (Bieschke et al., 2010; Caruana et al.,
2011). However, the effect of EGCG on SYN oligomerization
and fibrillization in vivo remained uninvestigated thus far.
To evaluate the effect of FK506 and EGCG on SYN oli-
gomerization in cell culture, SHSY5Y cells expressing FlucN-
SYN SYN-FlucC were exposed to either 10M FK506 or 25
M EGCG. To verify whether FK506 and EGCG influence the
enzymatic activity of full-length Fluc, 10 M FK506 or 25 M
EGCG were also added to cells expressing eGFP-T2A-Fluc. No
significant effects of the compounds on FLuc activity were ob-
served (data not shown). In cells expressing FlucN-SYN 
SYN-FlucC, addition of 10 M FK506 resulted in a 33% reduc-
tion in SYN oligomerization compared with DMSO (Fig. 7A;
p 0.001), whereas EGCG did not affect SYN oligomerization
(Fig. 7A). Biochemical analysis of cells expressing FlucN-SYN
SYN-FlucC treated with FK506 showed a reduction in the
amount of SYN oligomers after cross-linking compared with
cells treated with DMSO (Fig. 7A).
Next, we evaluated the effect of chronic administration of
FK506 and EGCG on SYN oligomerization in the mouse stria-
tum. A mixture of FlucN-SYN SYN-FlucC AAV vectors (a
total of 7.6 108 GC per animal) was stereotactically injected in
the striatum of albino mice (n 8–16 per treatment group). To
verify whether FK506 and EGCG influence the enzymatic activity
of full-length Fluc in vivo, control animals were stereotactically
injected with eGFP-T2A-Fluc AAV (n  4–8 per treatment
group). Remarkably, in the latter group, FK506 treatment re-
sulted in a twofold higher BLI signal compared with placebo
treatment at all time points investigated (Fig. 7B; p 0.05). Be-
cause this might eventually confound the interpretation when
evaluating the effect of FK506 on SYN oligomerization, the BLI
Figure 7. Effects of FK506 and EGCG onSYN oligomer formation in cell culture and in mouse brain. A, Left, FK506 or EGCG was added to SHSY5Y cells stably overexpressing FlucN-SYN
SYN-FlucC or overexpressing eGFP-T2A-Fluc, to verify the effect on luciferase activity of full-length Fluc. The luciferase activity from cells expressing FlucN-SYNSYN-FlucC was normalized
toDMSOand to the luciferase activity of cells expressing eGFP-T2A-Fluc. Addition of 10M FK506 resulted in a 33% inhibition ofSYNoligomerization comparedwithDMSO. Data aremean SEM
from four independent experiments (n 24 per condition). Statistical analysis: one-way ANOVA combined with Bonferroni correction for multiple testing (F(2,69) 7.64). ***p 0.001. Right,
Biochemical analysis of cells overexpressing FlucN-SYNSYN-FlucC treated with 10M FK506 or DMSO. FK506 treatment resulted in a 23% reduction in the oligomer/monomer ratio ( p
0.09; n 3). Immunodetection was performed with the 15G7 antibody. B, Albino mice were stereotactically injected with eGFP-T2A-Fluc AAV in the striatum and received chronic treatment of 5
mg/kg/d FK506 (n8), 20mg/kg/d EGCG (n4), or placebo (n8). FK506 treatment resulted in a twofoldhigher BLI signal comparedwith theplacebogroupat all timepoints. Data aremean
SEM from two independent experiments. Statistical analysis: two-way repeated-measures ANOVA combined with Bonferroni correction for multiple testing (F(1,42) 4.49, p 0.052). Bottom,
Representative bioluminescent images.C, Albinomicewere stereotactically injectedwith FlucN-SYNSYN-FlucCAAVs in the striatumand received chronic treatment of 5mg/kg/d FK506 (n
13), 20mg/kg/d EGCG (n 8), or placebo (n 16). The BLI signal frommice expressing FlucN-SYNSYN-FlucC was normalized to that of mice expressing eGFP-T2A-Fluc, per treatment and
per time point. FK506 treatment inhibitedSYN oligomerization starting from 3weeks after injection, resulting in a 3.6-fold inhibition comparedwith the placebo group at 4 weeks after injection
Data are mean SEM from two independent experiments. Statistical analysis: two-way repeated-measures ANOVA combined with Bonferroni correction for multiple testing (F(2,102) 1.97).
**p 0.01. Right, Representative bioluminescent images.
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signal from mice expressing FlucN-SYN  SYN-FlucC was
normalized to that of mice expressing eGFP-T2A-Fluc, per treat-
ment and per time point. In mice expressing FlucN-SYN 
SYN-FlucC that received placebo treatment, the BLI signal
gradually increased reaching a fourfold difference between 1 and
4 weeks after injection, which is in line with the previous results
(Figs. 7C and 4B). Compared with the placebo group, mice
treated with FK506 showed a decrease in BLI signal from 3 weeks
onwards, resulting in a 3.6-fold inhibition after 4 weeks of treat-
ment (Fig. 7C; p 0.01). In linewith the cell culture experiments,
EGCG did not affect the BLI signal (Fig. 7C). FK506 thus inhibits
SYN oligomerization both in cell culture and in mouse brain.
Discussion
Increasing evidence identifies SYN oligomers as the toxic spe-
cies in the pathogenesis of PD and other synucleinopathies. Con-
sequently, the development of new methods to monitor SYN
oligomers in cell culture and in living animals is crucial. We
designed a bioluminescent split-Fluc complementation assay, al-
lowing us to detectSYNoligomers in cultured cells and to image
SYN oligomerization noninvasively in mouse brain.
SYN oligomers can be identified using conformation-
specific antibodies (Kayed et al., 2003; Lindersson et al., 2004;
Fagerqvist et al., 2013). Alternatively, a fluorescent PCA based on
split-GFP reporters was implemented for visualization of SYN
oligomers in cultured cells (Outeiro et al., 2008). Using a split-
Venus PCA, SYN oligomers were detected in the cortex via
2-photon microscopy (Dimant et al., 2013). However, the slow
and irreversible chromophore formation does not allow real-
time monitoring of protein–protein interactions. Additionally,
2-photon microscopy does not support imaging in deep brain
structures. Because complementation of luciferases is reversible,
bioluminescent PCAs have a high temporal resolution, allowing
near-real-time association studies. Moreover, these assays have
an excellent signal-to-noise ratio and sensitivity. A biolumines-
cent PCA based on split-Gluc was developed to studymodulators
of SYN oligomerization (Putcha et al., 2010). However, the
spectral properties of Gluc and inability of the substrate coelen-
terazine to cross an intact BBB preclude using this system for
neuroimaging in live animals. For all these reasons, we designed a
bioluminescent PCA based on split-Fluc.
Split-Fluc LV vectors were optimized to monitor SYN oli-
gomers in cell culture. The combination of both split-SYN LV
vectors resulted in aBLI signal11-fold higher than control cells.
Next, split-Fluc AAV vectors were used to noninvasively image
SYN oligomerization in mouse brain. Both in the striatum and
in the SN, the combination of both split-SYN AAV vectors re-
sulted in a BLI signal sixfold higher than in controls, indicating
that interaction between two or more SYN proteins results in
efficient luciferase complementation.
An important aspect to consider is whether the visualized
SYN oligomers are pathologically relevant species. In cell cul-
ture, induction of aggregation under oxidative stress conditions
was comparable with untagged WT SYN, demonstrating that
the aggregation properties of SYN are not altered by the Fluc
tags. In mouse brain, Fluc-tagged SYN species were ubiquiti-
nated, a hallmark of LB pathology (Kuzuhara et al., 1988; Tofaris
et al., 2003). Moreover, aggregated and phosphorylated S129p
SYN species, the most dominant pathological modification of
SYN in LBs (Anderson et al., 2006), were detected. Further-
more, injection of the split-Fluc SYN vectors in the SN led to
extensive dopaminergic degeneration, in agreement with our re-
cently developed PD mouse model based on AAV-mediated
overexpression of untagged WT SYN (Oliveras-Salva´ et al.,
2013). Because loss of transduced dopaminergic neurons in the
SN might confound correct interpretation of the BLI signal, the
striatummight be the preferential brain region for the evaluation
of modulators of SYN oligomerization.
To evaluate which SYN oligomers contribute to the BLI sig-
nal, we applied a cross-linking protocol. Different sizes of oli-
gomers, ranging from dimers to HMW oligomers, were detected
both in cell culture and in mouse brain. In cell culture, the BLI
signal only arises from SYN oligomers because very specific
culture conditions (e.g., oxidative stress) are necessary to induce
SYN to form fibrils. In vivo, interaction between at least two
SYNmolecules results in complementation of Fluc, reflected by
the sixfold higher BLI signal when both split-SYN AAV vectors
were injected. However, we cannot judge on the exact type and
size of SYN oligomers contributing to the signal, nor can we
exclude that SYN fibrils are partially responsible for the BLI
signal in vivo. Nevertheless, one could hypothesize that HMW
oligomers and fibrils possess limited luciferase activity due to
sterical hindrance resulting in impeded complementation of the
two Fluc fragments (Luker et al., 2004; Stynen et al., 2012).
The major asset of noninvasive molecular imaging is that it
allows quantitative analysis of a biological process in the same
group of animals over time, yielding better quality results from
far fewer experimental animals (Massoud and Gambhir, 2003).
In both the striatum and the SN, the BLI signal is characterized by
an initial increase, followed by a decrease and eventually a stabi-
lization. Interestingly, mice injected with eGFP-T2A-Fluc AAV
showed a stable BLI signal from 1 until 4 weeks after injection,
indicating that the observed fluctuating kinetics in mice injected
with the split-Fluc vectors can be ascribed to SYN oligomeriza-
tion. The initial increase probably reflects a combination of acti-
vation of gene expression in all groups, but more importantly, a
continuous increase in production of SYN oligomers, reflected
by the more pronounced increase in BLI signal in the groups
injected with two split-Fluc-SYN vectors compared with the
control groups. The following decrease in BLI signal might be
explained by disappearance of transduced cells due to cell death.
However, histology revealed a distinct neurodegeneration only in
the SN,whichmight explain the earlier decline inBLI signal in the
SN (starting from 1–3 weeks after injection) compared with the
striatum (starting from 3–5 weeks after injection). Therefore,
another event must be responsible for the decline in BLI signal in
the striatum. We hypothesize that the continuous production of
oligomers and the conversion of these oligomers into fibrils with
limited luciferase activity take place in parallel. Consequently, we
suggest that the oligomerization of SYN is the predominant
process during the initial increase in BLI signal. A threshold is
reached between 3 and 5 weeks after injection, after which the
conversion into fibrils is the predominant process. The stabiliza-
tion is then explained by a steady state between these two pro-
cesses. To verify this hypothesis, one could test artificial mutants
that show a strongly reduced formation of amyloid fibrils and a
strongly increased propensity to oligomerize (Karpinar et al.,
2009; Winner et al., 2011).
We previously showed that FK506 inhibitsSYN fibrillization
through the inhibition of FKBP12 (Gerard et al., 2006, 2010).
However, one potential risk when inhibiting one step in an ag-
gregation pathway is that accumulation of harmful oligomers
could make toxicity worse (Ross and Poirier, 2004). In the pres-
ent study, we show that FK506 also inhibits oligomerization, both
in cell culture and in mouse brain, further validating FKBPs as a
drug target for PD and other synucleinopathies (Gerard et al.,
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2011). To show a direct link between FKBPs andSYNoligomer-
ization, nonimmunosuppressive analogs of FK506 or overex-
pression or knockdown of FKBP12 should be evaluated with our
split-Fluc technology. Of note, our finding that FK506 increased
the BLI signal after injection with eGFP-T2A-Fluc AAV empha-
sizes the importance of full-length Fluc as an internal control
when evaluating the effect of a small molecule. The immunosup-
pressive properties of FK506 might have resulted in improved
AAV vector transduction in mouse brain, eventually leading to
elevated expression levels of Fluc (Ren et al., 2010), although
there was no direct evidence of higher transgene expression levels
in our experiments. Alternatively, FK506 is known to increase the
permeability of the BBB (Kochi et al., 1999; Quezada et al., 2008),
which might result in higher availability of D-luciferin and sub-
sequently higher BLI signals.
EGCG can efficiently pass an intact BBB (Suganuma et al.,
1998) and has shown neuroprotective effects in animal models of
different neurodegenerative diseases (Mandel et al., 2011).More-
over, EGCG inhibits SYN oligomer and fibril formation in vitro
and in cultured cells (Ehrnhoefer et al., 2008; Bieschke et al., 2010;
Caruana et al., 2011), but the effect in vivo remained unexplored.
In the present study, EGCG did not affect SYN oligomerization
neither in cell culture nor in mouse brain. One possible explana-
tion is that EGCGdirectly binds toSYNmonomers and remod-
els them into off-pathway oligomers (Ehrnhoefer et al., 2008;
Caruana et al., 2011), which might not be distinguishable from
on-pathway oligomers with our split-Fluc technology. Addition-
ally, compared with studies in transgenic Alzheimer’s disease
mice (Rezai-Zadeh et al., 2005, 2008), our mice received EGCG
for a shorter time period and probably have higher protein ex-
pression level per cell due to viral transduction. It would there-
fore still be interesting to test EGCG in SYN transgenic mice.
Our bioluminescent PCA opens opportunities for library
screening of small-molecule inhibitors of oligomerization in cell
culture and validation of identified hits in vivo (Chan et al., 2012;
Takakura et al., 2012). Moreover, increasing information sup-
ports the notion that prefibrillar oligomers are the main toxic
species in different neurological proteinopathies (Ross and
Poirier, 2004; Gadad et al., 2011). Our technological approach
would allow to study oligomerization of amyloid- (Hashimoto
et al., 2011) and tau in Alzheimer’s disease, prion protein in Pri-
on’s disease, huntingtin in Huntington’s disease, or TDP-43 in
amyotrophic lateral sclerosis.
In conclusion, we report a new powerful technique that allows
to visualize SYN oligomers in cell culture and in mouse brain.
The value of this technology is evidenced by its use to provide new
insights into the role of small molecules on SYN oligomerization.
More specifically, we have demonstrated that the FKBP inhibitor
FK506 reduces SYN oligomerization in cell culture and in mouse
brain. This technique opens new perspectives in the quest for neu-
roprotective therapies for PD and other synucleinopathies.
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